Dr. Arny Glazier, a cancer researcher, feels that deeply held assumptions, theories and dogmas about cancer are not tenable given the fundamental evolutionary nature of the disease. He has published a book, "Cure: Scientific, Social, and Organizational Requirements for the Specific Cure of Cancer." The book, which was written for both scientists and non-scientists, explains tumor cell evolution and its logical implications.
He feels that cancer is about the properties of evolutionary populations of cells. He believes that the diverse, evolutionary nature of cancer implies that the required target for the consistent and specific cure or control of cancer is "the set of all malignant cells that could evolve."
To him, the consistent and specific cure or control of cancer will require developing a set of drugs, given in combination, targeted to patterns of normal cellular machinery related to proliferation and invasiveness. These requirements define a rational, practical strategy to develop curative therapy for all forms of solid cancer. A sufficient number of independent methods of cell killing must be employed so that it is too improbable for a cancer cell to evolve that can escape death or inactivation. It must examine every cell in the body and must do so for a prolonged period of time.
Although his book may argue against the notion of personalized therapy tailored to the individual's cancer cells, given the current state of the art, in vitro drug sensitivity testing could be of significant clinical value to his premise. If an in vitro drug resistance test can demonstrate the presence of cancer cells that are resistant to a drug combination, then it is rational to use alternative therapy. If an in vitro drug sensitivity test has the ability to demonstrate which drug combinations would be synergistic to cell death in all cancer cells present, then it is rational to use the drugs indicated in the test.
Cell culture assays, using the whole cell profiling method, can assess the activity of a drug upon combined effect of all cellular process, using combined metabolic (cell metabolism) and morphologic (structure) endpoints, at the cell population level, measuring the interaction of the entire genome.
I feel the book is well worth the reading for anyone wanting a better understanding about the fight against cancer. It is available at: http://www.lulu.com/content/276115